Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Caitlin E Wolfe

2 papers in the library · 5 citations · publishing 2022-2025

Papers

Comparison of Laboratory Confirmed Drugs in Acute Recreational Drug Toxicity Presentations to an Urban Hospital in London, UK, 2016/17 versus 2019/20.

Journal of medical toxicology : official journal of the American College of Medical Toxicology January 1, 2025 Caitlin E Wolfe, Lachlan J Sund, John Rh Archer et al. 5 citations

In 2021, 258 UK deaths were attributed to novel psychoactive substances (NPS). Confirmatory testing for NPS is limited by cost and speed. Among 1000 acute recreational drug toxicity presentations to a central London hospital in 2019/20, 28 unique NPS were detected, compared to 31 in a 2016/17 cohort. Eight new NPS appeared in 2019/20: four benzodiazepines, two synthetic cannabinoid receptor agonists, one cathinone, and one ketamine analogue. No NPS opioids were found in either cohort. Cannabis, ketamine, and opioid detection increased significantly from 2016/17 to 2019/20, while alcohol, cathinones, GHB, and MDMA decreased. The findings align with European forensic trends and underscore the need for ongoing surveillance of emerging drugs.

Linking in vitro and ex vivo CB1 activity with serum concentrations and clinical features in 5F-MDMB-PICA users to better understand SCRAs and their metabolites.

Archives of Toxicology November 1, 2022 Liesl K Janssens, Simon Hudson, David M Wood et al.

In 71 patients who used the synthetic cannabinoid 5F-MDMB-PICA, serum concentrations of the drug correlated with ex vivo activation of the CB1 cannabinoid receptor in a sigmoidal pattern. Two active metabolites were identified, but their overall contribution to cannabinoid activity in serum was negligible. Clinically, higher ex vivo cannabinoid activity was associated with a significant decrease in the Glasgow Coma Scale score, indicating reduced consciousness. In vitro pharmacological profiling could predict an individual's ex vivo CB1 activity, which in turn related to level of consciousness.